Scientific Focus

Angiomedix builds on our clinical research showing that invasive coronary function testing—wire‑based coronary physiology assessment paired with pharmacologic provocation using acetylcholine—accurately identifies microvascular disease and vasospasm, and guides targeted therapy.

Acetylcholine is a naturally occurring neurotransmitter that plays a key role in regulating vascular tone by stimulating the endothelium—the inner lining of blood vessels—to release nitric oxide and cause vasodilation. In coronary arteries, this response reflects healthy endothelial function. When acetylcholine is administered during coronary function testing, abnormal reactions such as impaired dilation or paradoxical constriction (vasospasm) reveal underlying microvascular dysfunction or vasomotor disorders. These conditions are major contributors to ischemic heart disease in patients without large-artery blockages, making acetylcholine a critical tool for diagnosing INOCA and guiding targeted therapy.

Routine tools (ECG, echocardiograms, stress tests) often miss these disorders, and advanced tests like PET or cardiac MRI can detect microvascular disease but not vasospasm and are concentrated at a limited number of centers. The result is delayed or incorrect diagnoses, undertreatment, and greater morbidity and higher cost. 

Our streamlined, safety‑tested protocol for coronary function testing uses standard cath‑lab equipment, is already in routine use across dozens of hospitals, and has been evaluated prospectively in the DISCOVER INOCA multi‑center registry, a study designed and led by our team. 

To unlock broad access, we are developing stability‑tested, pre‑filled single‑dose acetylcholine syringes, pursuing FDA pathways for on‑label cardiovascular use, and working with professional societies on a dedicated CPT code and reimbursement—steps designed to catalyze adoption system‑wide.